One theory is that metformin taken during insulin treatment impacts energy intake and so supports weight loss. A quick look at a new study suggests something else.
Click through these 5 statements about the "gliflozin" class of diabetes drugs for a test of your recall and retention.
The first-to-market hybrid closed loop CGM and "smart" insulin pens are 2 of our picks for 2017’s best tech advances in diabetes management.
Five studies on the impact of diabetes drugs on CV outcomes get the editors' nod for the most promising results in 2017 diabetes research. Find out which 5!
ShugaTrak, Glucose Buddy, OnTrack -- 3 of the 5 apps we highlight that are designed to make diabetes monitoring seamless for all.
What's true and what's false about the connections between these often comorbid conditions? These 10 statements will test what you know.
Five slides, 5 snapshots of products that help reduce fingerstick anxiety, enhance medication adherence, and prevent plantar ulcers.
The AACE/ACE 2017 recommendations on lipid management renew focus on LDL-C targets, and go far lower than any group has ventured to date.
Significant reductions were seen in MACE, renal disease progression in patients with high CV risk taking canagliflozin.
Can you sort out diabetes facts from fiction? The latest diabetes statistics from the CDC may surprise you.